Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 8K filed

"Company agreed to certain additional allocations of obligations relating to the Program Agreement."

So, does this mean that Leckrone has found a way to get PTSC to pay even more of the costs? I don't see any mention of a reduction in TPLs' "off the top" cut from income, nor of PTSC gaining a majority interest in PDS.

Anyone read it differently?

Share
New Message
Please login to post a reply